Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.

Kirkegaard T, Hansen SK, Larsen SL, Reiter BE, Sørensen BS, Lykkesfeldt AE.

Cancer Lett. 2014 Mar 1;344(1):90-100. doi: 10.1016/j.canlet.2013.10.014.

PMID:
24513268
2.

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Larsen SL, Laenkholm AV, Duun-Henriksen AK, Bak M, Lykkesfeldt AE, Kirkegaard T.

PLoS One. 2015 Feb 23;10(2):e0118346. doi: 10.1371/journal.pone.0118346. eCollection 2015.

3.

Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines.

Sommer A, Hoffmann J, Lichtner RB, Schneider MR, Parczyk K.

J Steroid Biochem Mol Biol. 2003 May;85(1):33-47.

PMID:
12798355
4.

Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.

Larsen SS, Egeblad M, Jäättelä M, Lykkesfeldt AE.

Breast Cancer Res Treat. 1999 Nov;58(1):41-56.

PMID:
10634517
5.

Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.

Yeh WL, Shioda K, Coser KR, Rivizzigno D, McSweeney KR, Shioda T.

PLoS One. 2013 Apr 4;8(4):e60889. doi: 10.1371/journal.pone.0060889. Print 2013.

6.

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.

Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE, Knowlden JM, Nicholson RI, Gee JM.

Breast Cancer Res. 2011 Mar 11;13(2):R29. doi: 10.1186/bcr2848.

7.

The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines.

Kirkegaard T, Yde CW, Kveiborg M, Lykkesfeldt AE.

Int J Oncol. 2014 Jul;45(1):393-400. doi: 10.3892/ijo.2014.2434. Epub 2014 May 9.

PMID:
24819550
8.

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.

Larsen SL, Yde CW, Laenkholm AV, Rasmussen BB, Duun-Henriksen AK, Bak M, Lykkesfeldt AE, Kirkegaard T.

BMC Cancer. 2015 Apr 8;15:239. doi: 10.1186/s12885-015-1210-4.

9.

Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.

Morrison G, Fu X, Shea M, Nanda S, Giuliano M, Wang T, Klinowska T, Osborne CK, Rimawi MF, Schiff R.

Breast Cancer Res Treat. 2014 Apr;144(2):263-72. doi: 10.1007/s10549-014-2878-x. Epub 2014 Feb 20.

10.

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Thrane S, Pedersen AM, Thomsen MB, Kirkegaard T, Rasmussen BB, Duun-Henriksen AK, Lænkholm AV, Bak M, Lykkesfeldt AE, Yde CW.

Oncogene. 2015 Aug 6;34(32):4199-210. doi: 10.1038/onc.2014.351. Epub 2014 Nov 3.

PMID:
25362855
11.

interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant).

Bouker KB, Skaar TC, Fernandez DR, O'Brien KA, Riggins RB, Cao D, Clarke R.

Cancer Res. 2004 Jun 1;64(11):4030-9.

12.

NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.

Yde CW, Emdal KB, Guerra B, Lykkesfeldt AE.

Breast Cancer Res Treat. 2012 Aug;135(1):67-78. doi: 10.1007/s10549-012-2053-1. Epub 2012 Apr 18.

PMID:
22527100
13.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.

Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28.

14.

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.

Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.

Int J Cancer. 2010 Jan 15;126(2):545-62. doi: 10.1002/ijc.24750.

15.

Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.

Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price L, Meerman J, van de Water B.

Breast Cancer Res. 2011 May 19;13(3):R52. doi: 10.1186/bcr2883.

16.

Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression.

Shibata T, Watari K, Izumi H, Kawahara A, Hattori S, Fukumitsu C, Murakami Y, Takahashi R, Toh U, Ito KI, Ohdo S, Tanaka M, Kage M, Kuwano M, Ono M.

Cancer Res. 2017 Jan 15;77(2):545-556. doi: 10.1158/0008-5472.CAN-16-1593. Epub 2016 Nov 22.

17.

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.

J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.

PMID:
15199112
18.

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.

Ikeda H, Taira N, Hara F, Fujita T, Yamamoto H, Soh J, Toyooka S, Nogami T, Shien T, Doihara H, Miyoshi S.

Breast Cancer Res. 2010;12(3):R43. doi: 10.1186/bcr2598. Epub 2010 Jun 28.

19.

Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.

Ishii Y, Papa L, Bahadur U, Yue Z, Aguirre-Ghiso J, Shioda T, Waxman S, Germain D.

Clin Cancer Res. 2011 Apr 15;17(8):2292-300. doi: 10.1158/1078-0432.CCR-10-1745. Epub 2011 Feb 3.

20.

Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals.

Huang J, Woods P, Normolle D, Goff JP, Benos PV, Stehle CJ, Steinman RA.

Breast Cancer Res Treat. 2017 Jan;161(2):229-243. doi: 10.1007/s10549-016-4052-0. Epub 2016 Nov 16.

Supplemental Content

Support Center